|
1
|
Forastiere A, Koch W, Trotti A and
Sidransky D: Head and neck cancer. N Engl J Med. 345:1890–1900.
2001. View Article : Google Scholar
|
|
2
|
Mashberg A, Boffetta P, Winkelman R and
Garfinkel L: Tobacco smoking, alcohol drinking, and cancer of the
oral cavity and oropharynx among U.S. veterans. Cancer.
72:1369–1375. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Neville BW and Day TA: Oral cancer and
precancerous lesions. CA Cancer J Clin. 52:195–215. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liang XH, Lewis J, Foote R, Smith D and
Kademani D: Prevalence and significance of human papillomavirus in
oral tongue cancer: the Mayo Clinic experience. J Oral Maxillofac
Surg. 66:1875–1880. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gordaliza M: Natural products as leads to
anticancer drugs. Clin Transl Oncol. 9:767–776. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rasheed WK, Johnstone RW and Prince HM:
Histone deacetylase inhibitors in cancer therapy. Expert Opin
Investig Drugs. 16:659–678. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vigushin DM and Coombes RC: Histone
deacetylase inhibitors in cancer treatment. Anticancer Drugs.
13:1–13. 2002. View Article : Google Scholar
|
|
8
|
Lin HY, Chen CS, Lin SP, Weng JR and Chen
SC: Targeting histone deacetylase in cancer therapy. Med Res Rev.
26:397–413. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bolden JE, Peart MJ and Johnstone RW:
Anticancer activities of histone deacetylase inhibitors. Nat Rev
Drug Discov. 5:769–784. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Marks P, Rifkind RA, Richon VM, Breslow R,
Miller T and Kelly WK: Histone deacetylases and cancer: causes and
therapies. Nat Rev Cancer. 1:194–202. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Johnstone RW and Licht JD: Histone
deacetylase inhibitors in cancer therapy: is transcription the
primary target? Cancer Cell. 4:13–18. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Atadja P: Development of the pan-DAC
inhibitor panobinostat (LBH589): successes and challenges. Cancer
Lett. 280:233–241. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dokmanovic M, Clarke C and Marks PA:
Histone deacetylase inhibitors: overview and perspectives. Mol
Cancer Res. 5:981–989. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shao W, Growney JD, Feng Y, et al:
Activity of deacetylase inhibitor panobinostat (LBH589) in
cutaneous T-cell lymphoma models: Defining molecular mechanisms of
resistance. Int J Cancer. 127:2199–2208. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Maiso P, Carvajal-Vergara X, Ocio EM, et
al: The histone deacetylase inhibitor LBH589 is a potent
antimyeloma agent that overcomes drug resistance. Cancer Res.
66:5781–5789. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Giles F, Fischer T, Cortes J, et al: A
phase I study of intravenous LBH589, a novel cinnamic hydroxamic
acid analogue histone deacetylase inhibitor, in patients with
refractory hematologic malignancies. Clin Cancer Res. 12:4628–4635.
2006. View Article : Google Scholar
|
|
17
|
Gupta SC, Kim JH, Prasad S and Aggarwal
BB: Regulation of survival, proliferation, invasion, angiogenesis,
and metastasis of tumor cells through modulation of inflammatory
pathways by nutraceuticals. Cancer Metastasis Rev. 29:405–434.
2010. View Article : Google Scholar
|
|
18
|
Deniaud E, Baguet J, Mathieu AL, Pages G,
Marvel J and Leverrier Y: Overexpression of Sp1 transcription
factor induces apoptosis. Oncogene. 25:7096–7105. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jutooru I, Chadalapaka G, Sreevalsan S, et
al: Arsenic trioxide downregulates specificity protein (Sp)
transcription factors and inhibits bladder cancer cell and tumor
growth. Exp Cell Res. 316:2174–2188. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Schmitt CA and Lowe SW: Apoptosis and
therapy. J Pathol. 187:127–137. 1999. View Article : Google Scholar
|
|
21
|
Nagata S: Fas-induced apoptosis. Intern
Med. 37:179–181. 1998. View Article : Google Scholar
|
|
22
|
Green DR: Apoptotic pathways: paper wraps
stone blunts scissors. Cell. 102:1–4. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Marks PA, Richon VM and Rifkind RA:
Histone deacetylase inhibitors: inducers of differentiation or
apoptosis of transformed cells. J Natl Cancer Inst. 92:1210–1216.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Miller TA, Witter DJ and Belvedere S:
Histone deacetylase inhibitors. J Med Chem. 46:5097–5116. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Drummond DC, Noble CO, Kirpotin DB, Guo Z,
Scott GK and Benz CC: Clinical development of histone deacetylase
inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol.
45:495–528. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Minucci S and Pelicci PG: Histone
deacetylase inhibitors and the promise of epigenetic (and more)
treatments for cancer. Nat Rev Cancer. 6:38–51. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chao H, Wang L, Hao J, et al: Low dose
histone deacetylase inhibitor, LBH589, potentiates anticancer
effect of docetaxel in epithelial ovarian cancer via PI3K/Akt
pathway in vitro. Cancer Lett. 329:17–26. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Vallo S, Mani J, Stastny M, et al: The
prostate cancer blocking potential of the histone deacetylase
inhibitor LBH589 is not enhanced by the multi receptor tyrosine
kinase inhibitor TKI258. Invest New Drugs. 31:265–272. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Di Fazio P, Montalbano R, Neureiter D, et
al: Downregulation of HMGA2 by the pan-deacetylase inhibitor
panobinostat is dependent on hsa-let-7b expression in liver cancer
cell lines. Exp Cell Res. 318:1832–1843. 2012.PubMed/NCBI
|
|
30
|
Di Fazio P, Schneider-Stock R, Neureiter
D, et al: The pan-deacetylase inhibitor panobinostat inhibits
growth of hepatocellular carcinoma models by alternative pathways
of apoptosis. Cell Oncol. 32:285–300. 2010.
|
|
31
|
Chiefari E, Brunetti A, Arturi F, et al:
Increased expression of AP2 and Sp1 transcription factors in human
thyroid tumors: a role in NIS expression regulation? BMC Cancer.
2:352002. View Article : Google Scholar
|
|
32
|
Hosoi Y, Watanabe T, Nakagawa K, et al:
Up-regulation of DNA-dependent protein kinase activity and Sp1 in
colorectal cancer. Int J Oncol. 25:461–468. 2004.PubMed/NCBI
|
|
33
|
Wang L, Wei D, Huang S, et al:
Transcription factor Sp1 expression is a significant predictor of
survival in human gastric cancer. Clin Cancer Res. 9:6371–6380.
2003.
|
|
34
|
Yao JC, Wang L, Wei D, et al: Association
between expression of transcription factor Sp1 and increased
vascular endothelial growth factor expression, advanced stage, and
poor survival in patients with resected gastric cancer. Clin Cancer
Res. 10:4109–4117. 2004. View Article : Google Scholar
|
|
35
|
Zannetti A, Del Vecchio S, Carriero MV, et
al: Coordinate up-regulation of Sp1 DNA-binding activity and
urokinase receptor expression in breast carcinoma. Cancer Res.
60:1546–1551. 2000.PubMed/NCBI
|
|
36
|
Davie JR, He S, Li L, et al: Nuclear
organization and chromatin dynamics-Sp1, Sp3 and histone
deacetylases. Adv Enzyme Regul. 48:189–208. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li L and Davie JR: The role of Sp1 and Sp3
in normal and cancer cell biology. Ann Anat. 192:275–283. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Duan H, Heckman CA and Boxer LM: Histone
deacetylase inhibitors down-regulate bcl-2 expression and induce
apoptosis in t(14;18) lymphomas. Mol Cell Biol. 25:1608–1619. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wilson AJ, Chueh AC, Togel L, et al:
Apoptotic sensitivity of colon cancer cells to histone deacetylase
inhibitors is mediated by an Sp1/Sp3-activated transcriptional
program involving immediate-early gene induction. Cancer Res.
70:609–620. 2010. View Article : Google Scholar
|
|
40
|
Blume SW, Snyder RC, Ray R, Thomas S,
Koller CA and Miller DM: Mithramycin inhibits SP1 binding and
selectively inhibits transcriptional activity of the dihydrofolate
reductase gene in vitro and in vivo. J Clin Invest. 88:1613–1621.
1991. View Article : Google Scholar
|
|
41
|
Chintharlapalli S, Papineni S, Lei P,
Pathi S and Safe S: Betulinic acid inhibits colon cancer cell and
tumor growth and induces proteasome-dependent and -independent
downregulation of specificity proteins (Sp) transcription factors.
BMC Cancer. 11:3712011. View Article : Google Scholar
|
|
42
|
Pietrzak M and Puzianowska-Kuznicka M:
p53-dependent repression of the human MCL-1 gene encoding an
anti-apoptotic member of the BCL-2 family: the role of Sp1 and of
basic transcription factor binding sites in the MCL-1 promoter.
Biol Chem. 389:383–393. 2008. View Article : Google Scholar
|
